The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the
clinical management of patients with clear cell and non-clear cell renal carcinoma. These …

Background: The treatment landscape of metastatic renal cell carcinoma (mRCC) has
substantially advanced over the last three decades, whereby data from controlled clinical …

Simple Summary Non-clear cell renal cell carcinomas (ncRCC) make up a heterogeneous
group subclassified into different subtypes that differ in genetic and biochemical …

Objective: This study aimed to compare the safety profile of tyrosine kinase inhibitors (TKIs)
approved for use as monotherapy or combination therapy for the first-line treatment of adult …

There has been significant progress in the treatment of patients with advanced clear cell
renal cell carcinoma (ccRCC), with improved knowledge of disease biology and the …

The treatment paradigm for treatment-naive metastatic clear cell renal cell carcinoma
continued to evolve in 2019 as three phase III randomized controlled trials were reported …

Simple Summary Over the past two decades, biological discoveries have transformed the
treatment strategies for renal cell carcinoma. These advances have led to the development …

Opinion Statement With no therapy specifically approved for non-clear cell cancers of the
kidney, this disease remains an orphan site. Clear cell renal cancers (ccRCC) have seen a …

Treatment options for metastatic clear cell renal cell carcinoma (ccRCC) have evolved
markedly over the past decade, with multiple targeted therapies approved for the disease. In …

Simple Summary To summarize the main discoveries made over the past few years to treat
metastatic clear cell renal cell carcinoma, including different generations of anti-VEGF TKIs …